Julian Maurer
Overview
Explore the profile of Julian Maurer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
229
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang K, Fischer A, Maccio U, Zitzmann K, Robledo M, Lauseker M, et al.
Eur J Endocrinol
. 2025 Jan;
192(1):46-60.
PMID: 39804847
Objective: The effects of sex hormones remain largely unexplored in pheochromocytomas and paragangliomas (PPGLs) and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Methods: We evaluated the effects of estradiol, progesterone, Dehydroepiandrosterone sulfate (DHEAS),...
2.
Wang K, Schober L, Fischer A, Bechmann N, Maurer J, Peischer L, et al.
J Clin Endocrinol Metab
. 2024 Apr;
109(11):2892-2904.
PMID: 38605427
Context: Treatment options for advanced neuroendocrine tumors (NETs), pheochromocytomas and paragangliomas (PPGLs) are still limited. In recent years, antitumor effects of cannabinoids have been reported; however, there are only very...
3.
Fischer A, Kloos S, Remde H, Dischinger U, Pamporaki C, Timmers H, et al.
Eur J Endocrinol
. 2023 Nov;
189(5):546-565.
PMID: 37949483
Objective: The therapeutic options for metastatic pheochromocytomas/paragangliomas (mPPGLs) include chemotherapy with cyclophosphamide/vincristine/dacarbazine (CVD), temozolomide monotherapy, radionuclide therapies, and tyrosine kinase inhibitors such as sunitinib. The objective of this multicenter retrospective...
4.
Mohan A, Prasad S, Schmitz-Peiffer F, Lange C, Lukas M, Koziolek E, et al.
Endocr Relat Cancer
. 2023 Nov;
31(1).
PMID: 37943630
The mechanistic target of rapamycin complex 1 (mTORC1) inhibitor everolimus is one of the few approved therapies for locally advanced and metastatic neuroendocrine tumours (NETs). However, after initial disease stabilisation,...
5.
Fischer A, Kloos S, Maccio U, Friemel J, Remde H, Fassnacht M, et al.
J Clin Endocrinol Metab
. 2023 Mar;
108(10):2676-2685.
PMID: 36946182
Context: Pheochromocytomas and paragangliomas (PPGLs) with pathogenic mutations in the succinate dehydrogenase subunit B (SDHB) are associated with a high metastatic risk. Somatostatin receptor 2 (SSTR2)-dependent imaging is the most...
6.
Maurer J, Walles T, Wiese-Rischke C
Int J Mol Sci
. 2023 Feb;
24(4).
PMID: 36835529
In vitro airway models are increasingly important for pathomechanistic analyses of respiratory diseases. Existing models are limited in their validity by their incomplete cellular complexity. We therefore aimed to generate...
7.
Wang K, Schutze I, Gulde S, Bechmann N, Richter S, Helm J, et al.
Endocr Relat Cancer
. 2022 Mar;
29(6):285-306.
PMID: 35324454
Aggressive pheochromocytomas and paragangliomas (PPGLs) are difficult to treat, and molecular targeting is being increasingly considered, but with variable results. This study investigates established and novel molecular-targeted drugs and chemotherapeutic...
8.
Jin X, Spottl G, Maurer J, Nolting S, Auernhammer C
Cancers (Basel)
. 2021 Apr;
13(6).
PMID: 33807122
Objectives: This study assessed the antitumoral activity of the MEK inhibitor trametinib (TMT212) and the ERK1/2 inhibitor SCH772984, alone and in combination with the CDK4/6 inhibitor ribociclib (LEE011) in human...
9.
Jin X, Spoettl G, Maurer J, Nolting S, Auernhammer C
Cancers (Basel)
. 2020 Feb;
12(2).
PMID: 32033025
Background And Aims: Inhibition of Wnt/β-catenin signaling by specific inhibitors is currently being investigated as an antitumoral strategy for various cancers. The role of Wnt/β-catenin signaling in neuroendocrine tumors still...
10.
Siebert C, Ciato D, Murakami M, Frei-Stuber L, Perez-Rivas L, Monteserin-Garcia J, et al.
Front Endocrinol (Lausanne)
. 2019 Aug;
10:487.
PMID: 31379752
Adrenocortical carcinoma (ACC) is a rare tumor entity with restricted therapeutic opportunities. HSP90 (Heat Shock Protein 90) chaperone activity is fundamental for cell survival and contributes to different oncogenic signaling...